GE HealthCare to Acquire Sofie Biosciences for $945 Million

GE HealthCare announced an agreement to acquire Sofie Biosciences for $945 million in cash. The transaction is expected to close in the first half of 2027 and is designed to vertically integrate the company's radiopharmaceuticals portfolio while adding a phase 3 asset to its pipeline.

The acquisition follows a strong second-quarter financial performance for GE HealthCare, which reported $5.295 billion in revenue. This figure represented 3.5% organic growth and exceeded market consensus expectations.

Financial analysts responded positively to the deal. Needham reiterated a Buy rating and a $93.00 price target, stating the acquisition should be accretive to revenue growth, operating margin, and earnings per share within the first full year. RBC Capital also maintained an Outperform rating and an $80.00 price target.